Warner Chilcott gets FDA for Oral Contraceptive
FYI: Warner Chilcott is focused on the women’s healthcare, gastroenterology, urology and dermatology areas of the branded pharmaceuticals market
ROCKAWAY, NJ: Warner Chilcott PLC (WCRX) obtained U.S. Food and Drug Administration approval of the oral contraceptive Minastrin 24 FE.
The pharmaceutical company said it doesn’t expect to be in a position to commercially launch Minastrin 24 FE this year. The capsules are manufactured by a third party.
Warner Chilcott, a maker of prescription health-care and dermatology products for women, has seen declining revenue for more than a year amid sagging sales of Actonel. The osteoporosis treatment lost exclusivity in Europe and now faces increased generic competition in the U.S.
The company reported in February its fourth-quarter profit rose 38% as lower tax costs masked a 5.3% drop in revenue.
Shares closed Friday at $13.88 and were inactive premarket. The stock is up 15% since the start of the year.
ACLink: Warner Chilcott